Appendix 3; or (ii) by U.S. government employees and contract personnel solely for cybersecurity purposes. The Commission will not otherwise disclose any confidential business information in a manner that would reveal the operations of the firm supplying the information.

Summaries of Written Submissions: The Commission intends to publish summaries of the positions of interested persons in this report. If you wish to have a summary of your position included in an appendix to the report, please include a summary with your written submission and mark the summary as submitted for that purpose. The summary may not exceed 500 words, should be in MSWord format or a format that can be easily converted to MSWord, and should not include any confidential business information. The summary will be published as provided if it meets these requirements and is germane to the subject matter of the investigation. In the report the Commission will identify the name of the organization furnishing the summary and will include a link to the Commission’s Electronic Document Information System (EDIS) where the full written submission can be found.

By order of the Commission.

Lisa Barton,
Secretary to the Commission.

DEPARTMENT OF JUSTICE
Drug Enforcement Administration
[Docket No. DEA–920]
Importer of Controlled Substances Application: Fisher Clinical Services, Inc.

AGENCY: Drug Enforcement Administration, Justice.

ACTION: Notice of application.

SUMMARY: Fisher Clinical Services, Inc. has applied to be registered as an importer of basic class(es) of controlled substance(s). Refer to SUPPLEMENTARY INFORMATION listed below for further drug information.

DATES: Registered bulk manufacturers of the affected basic class(es), and applicants therefore, may file written comments on or objections to the issuance of the proposed registration on or before December 3, 2021. Such persons may also file a written request for a hearing on the application on or before January 3, 2022.

ADDRESSES: Written comments should be sent to: Drug Enforcement Administration, Attention: DEA Federal Register Representative/DPW, 8701 Morrissette Drive, Springfield, Virginia 22152.

SUPPLEMENTARY INFORMATION: In accordance with 21 CFR 1301.33(a), this is notice that on August 25, 2021, Fisher Clinical Services, Inc., 7554 Schantz Road, Allentown, Pennsylvania 18106–9032, applied to be registered as an importer of the following basic class(es) of controlled substance(s):

<table>
<thead>
<tr>
<th>Controlled substance</th>
<th>Drug code</th>
<th>Schedule</th>
</tr>
</thead>
<tbody>
<tr>
<td>Oxymorphone</td>
<td>9652</td>
<td>II</td>
</tr>
<tr>
<td>Fentanyl</td>
<td>9801</td>
<td>II</td>
</tr>
</tbody>
</table>

The company is a contract manufacturer. At the request of the company’s customers, it manufactures derivatives of the above controlled substances in bulk form. No other activities for these drug codes are authorized for this registration.

Brian S. Besser,
Acting Assistant Administrator.

[FR Doc. 2021–23982 Filed 11–2–21; 8:45 am]

BILLING CODE P

DEPARTMENT OF JUSTICE
Drug Enforcement Administration
[Docket No. DEA–921]
Bulk Manufacturer of Controlled Substances Application: Nanosyn Inc.

AGENCY: Drug Enforcement Administration, Justice.

ACTION: Notice of application.

SUMMARY: Nanosyn Inc. has applied to be registered as a bulk manufacturer of basic class(es) of controlled substance(s). Refer to SUPPLEMENTAL INFORMATION listed below for further drug information.

DATES: Registered bulk manufacturers of the affected basic class(es), and applicants therefore, may file written comments on or objections to the issuance of the proposed registration on or before January 3, 2022. Such persons may also file a written request for a hearing on the application on or before January 3, 2022.

ADDRESS: Written comments should be sent to: Drug Enforcement Administration, Attention: DEA Federal Register Representative/DPW, 8701 Morrissette Drive, Springfield, Virginia 22152.

SUPPLEMENTARY INFORMATION: In accordance with 21 CFR 1301.33(a), this is notice that on September 23, 2021, Nanosyn Inc., 3331 Industrial Drive, Suite B, Santa Rosa, California 95403–2062, applied to be registered as a bulk manufacturer of the following basic class(es) of controlled substance(s):

<table>
<thead>
<tr>
<th>Controlled substance</th>
<th>Drug code</th>
<th>Schedule</th>
</tr>
</thead>
<tbody>
<tr>
<td>Fentanyl</td>
<td>9801</td>
<td>II</td>
</tr>
<tr>
<td>Tapentadol</td>
<td>9780</td>
<td>II</td>
</tr>
<tr>
<td>Noroxymorphone</td>
<td>9668</td>
<td>II</td>
</tr>
<tr>
<td>Methylphenidate</td>
<td>9220</td>
<td>II</td>
</tr>
<tr>
<td>Levothyroxine</td>
<td>9220</td>
<td>II</td>
</tr>
<tr>
<td>Psilocybin</td>
<td>7437</td>
<td></td>
</tr>
<tr>
<td>Paxil</td>
<td>9668</td>
<td></td>
</tr>
<tr>
<td>Marihuana Extract</td>
<td>7350</td>
<td></td>
</tr>
</tbody>
</table>

The company plans to import the listed controlled substances for clinical trials only. No other activity for these drug codes is authorized for this registration.

Approval of permit applications will occur only when the registrant’s business activity is consistent with what is authorized under 21 U.S.C. 952(a)(2). Authorization will not extend to the import of Food and Drug Administration-approved or non-approved finished dosage forms for commercial sale.

Brian S. Besser,
Acting Assistant Administrator.

[FR Doc. 2021–23962 Filed 11–2–21; 8:45 am]

BILLING CODE 7020–02–P

DEPARTMENT OF JUSTICE
Drug Enforcement Administration
[Docket No. DEA–918]
Bulk Manufacturer of Controlled Substances Application: Groff Global

AGENCY: Drug Enforcement Administration, Justice.

ACTION: Notice of application.

SUMMARY: Groff Global has applied to be registered as a bulk manufacturer of basic class(es) of controlled substance(s). Refer to SUPPLEMENTARY INFORMATION listed below for further drug information.

<table>
<thead>
<tr>
<th>Controlled substance</th>
<th>Drug code</th>
<th>Schedule</th>
</tr>
</thead>
<tbody>
<tr>
<td>Marihuana Extract</td>
<td>7350</td>
<td></td>
</tr>
<tr>
<td>Psilocybin</td>
<td>7437</td>
<td></td>
</tr>
<tr>
<td>Methylphenidate</td>
<td>9220</td>
<td></td>
</tr>
<tr>
<td>Levothyroxine</td>
<td>9220</td>
<td></td>
</tr>
<tr>
<td>Paxil</td>
<td>9668</td>
<td></td>
</tr>
<tr>
<td>Noroxymorphone</td>
<td>9668</td>
<td></td>
</tr>
<tr>
<td>Tapentadol</td>
<td>9780</td>
<td></td>
</tr>
</tbody>
</table>

The company plans to import the listed controlled substances for clinical trials only. No other activity for these drug codes is authorized for this registration.

Approval of permit applications will occur only when the registrant’s business activity is consistent with what is authorized under 21 U.S.C. 952(a)(2). Authorization will not extend to the import of Food and Drug Administration-approved or non-approved finished dosage forms for commercial sale.

Brian S. Besser,
Acting Assistant Administrator.

[FR Doc. 2021–23897 Filed 11–2–21; 8:45 am]

BILLING CODE P
DATES: Registered bulk manufacturers of the affected basic class(es), and applicants therefore, may file written comments on or objections to the issuance of the proposed registration on or before January 3, 2022. Such persons may also file a written request for a hearing on the application on or before January 3, 2022.

ADDRESSES: Written comments should be sent to: Drug Enforcement Administration, Attention: DEA Federal Register Representative/DPW, 8701 Morrissette Drive, Springfield, Virginia 22152.

SUPPLEMENTARY INFORMATION: In accordance with 21 CFR 1301.33(a), this is notice that on September 8, 2021, Groff Global, 2218 South Queen Street, York, Pennsylvania 17402–4631, applied to be registered as a bulk manufacturer of the following basic class(es) of controlled substance(s):

<table>
<thead>
<tr>
<th>Controlled substance</th>
<th>Drug code</th>
<th>Schedule</th>
</tr>
</thead>
<tbody>
<tr>
<td>Psilocybin</td>
<td>7437</td>
<td>I</td>
</tr>
<tr>
<td>Psilocyn</td>
<td>7438</td>
<td>I</td>
</tr>
</tbody>
</table>

The company plans to bulk manufacture the listed controlled substances for internal use or for sale to its customers.

Brian S. Besser, Acting Assistant Administrator.
[FR Doc. 2021–23898 Filed 11–2–21; 8:45 am]
BILLING CODE 4510–24–P

DEPARTMENT OF LABOR

Bureau of Labor Statistics
Technical Advisory Committee; Notice of Meeting and Agenda

The Bureau of Labor Statistics Technical Advisory Committee will meet on Friday, November 19, 2021. This meeting will be held virtually from 10:00 a.m. to 4:00 p.m. EST.

The Committee presents advice and makes recommendations to the Bureau of Labor Statistics (BLS) on technical aspects of data collection and the formulation of economic measures and makes recommendations on areas of research. The BLS presents issues and then draws on the expertise of Committee members representing specialized fields within the academic disciplines of economics, statistics and data science, and survey design. The Federal Advisory Committee Act requires that agencies publish notice of an advisory committee meeting in the Federal Register.

The schedule and agenda for the meeting are as follows:
10:00 a.m. Commissioner’s Welcome and Review of Agency Developments
10:30 a.m. Insurance Claims Data in Medical Care Price Indexes
1:00 p.m. Generating New Data on Emerging Topics Using the New QCEW Business Supplement (QBS)
2:30 p.m. Adjusting Industry Measures of Hours Worked for Labor Composition
4:00 p.m. Approximate Conclusion

The meeting is open to the public. Any questions concerning the meeting should be directed to Sarah Dale, Bureau of Labor Statistics Technical Advisory Committee, at BLSTAC@bls.gov. Individuals planning to attend the meeting should register at https://blstac.eventbrite.com. Individuals who require special accommodations should contact Ms. Dale at least two days prior to the meeting date.

Signed at Washington, DC, this 27th day of October 2021.

[FR Doc. 2021–23894 Filed 11–2–21; 8:45 am]
BILLING CODE 4510–24–P

DEPARTMENT OF LABOR

Occupational Safety and Health Administration

[Notice.

Modification to the List of Appropriate NRTL Program Test Standards and the Scope of Recognition of Several NRTLs

AGENCY: Occupational Safety and Health Administration (OSHA), Labor.

ACTION: Notice.

SUMMARY: In this notice, OSHA announces the final decision to: (1) Add seven new test standards to the Nationally Recognized Testing Laboratories (NRTL) Program’s list of appropriate test standards; (2) delete or replace several test standards from the NRTL Program’s list of appropriate test standards; and (3) update the scope of recognition of several NRTLs.

DATES: The actions contained in this notice will become effective on November 3, 2021.

FOR FURTHER INFORMATION CONTACT: Information regarding this notice is available from the following sources: Press inquiries: Contact Mr. Frank Meilinger, Director, OSHA Office of Communications; telephone: (202) 693–1999; email: meilinger.francis2@dol.gov.

General and technical information: Contact Mr. Kevin Robinson, Director, Office of Technical Programs and Coordination Activities, Directorate of Technical Support and Emergency Management, Occupational Safety and Health Administration; telephone: (202) 693–2110 or email: robinson.kevin@dol.gov. OSHA’s web page includes information about the NRTL Program (see http://www.osha.gov/dts/otpca/nrtl/index.html).

SUPPLEMENTARY INFORMATION:

I. Background

The NRTL Program recognizes organizations that provide product-safety testing and certification services to manufacturers. These organizations perform testing and certification for purposes of the program, to U.S. consensus-based-product-safety test standards. The products covered by the NRTL Program consist of those items for which OSHA safety standards require “certification” by a NRTL. The requirements affect electrical products and 38 other types of products. OSHA does not develop or issue these test standards, but generally relies on standards development organizations (SDOs), which develop and maintain the standards using a method that provides input and consideration of views of industry groups, experts, users, consumers, governmental authorities and others having broad experience in the safety field involved.

A. Addition of New Test Standards to the NRTL List of Appropriate Test Standards

Periodically, OSHA will add new test standards to the NRTL list of appropriate test standards following an evaluation of the test standard document. To qualify as an appropriate test standard, the agency evaluates the document to (1) verify it represents a product category for which OSHA requires certification by a NRTL, (2) verify the document represents an end product and not a component, and (3) verify the document defines safety test specifications (not installation or operational performance specifications). OSHA becomes aware of new test standards through various avenues. For example, OSHA may become aware of new test standards by: (1) Monitoring notifications issued by certain SDOs; (2) reviewing applications by NRTLs or applicants seeking recognition to include a new test standard in their scope of recognition; and (3) obtaining notification from manufacturers, manufacturing organizations, government agencies, or other parties that a new test standard may be